Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-11-2012 | Original Article

Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease

Authors: David Garcia-Garcia, Pedro Clavero, Carmen Gasca Salas, Isabel Lamet, Javier Arbizu, Rafael Gonzalez-Redondo, Jose A. Obeso, Maria C. Rodriguez-Oroz

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 11/2012

Abstract

Purpose

Patients with Parkinson’s disease (PD) may have normal cognition, mild cognitive impairment (MCI) or dementia. We investigated differences in cerebral metabolism associated with these three cognitive states and the relationship between metabolism and cognitive dysfunction.

Methods

FDG PET and a battery of neuropsychological tests were used to study PD patients with dementia (n = 19), MCI (n = 28) and normal cognition (n = 21), and control subjects (n = 20). Regional glucose metabolism in patients and controls was analysed using statistical parametric mapping (SPM8) corrected for age, motor severity and depression. Correlations between the mini-mental state examination score and Z-score values of the different cognitive domains with respect to cerebral FDG uptake were assessed using SPM8.

Results

PD patients with MCI (PD-MCI patients) exhibited decreased FDG uptake in the frontal lobe, and to a lesser extent in parietal areas compared with cognitively normal patients. Patients with dementia showed reduced metabolism in the parietal, occipital and temporal areas and a less extensive reduction in the frontal lobe compared with PD-MCI patients, while widespread hypometabolism was seen in comparison with patients with normal cognition. PD-MCI patients exhibited reduced FDG uptake in the parietal and occipital lobes and in localized areas of the frontal and temporal lobes compared with controls, whereas patients with dementia showed a widespread reduction of cortical metabolism. Mini-mental state examination score correlated positively with metabolism in several lobes, executive function with metabolism in the parietooccipitotemporal junction and frontal lobe, memory with temporoparietal metabolism, visuospatial function with occipitoparietal and temporal metabolism, and language with frontal metabolism.

Conclusion

PD patients with MCI exhibited hypometabolism in several cortical regions compared with controls, and in the frontal and parietal regions compared with cognitively normal patients. Hypometabolism was higher in patients with dementia than in those with MCI, mainly in the posterior cortical areas where it was correlated with visuospatial, memory and executive functions.

Available only for authorised users

Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord. 2005;20(10):1255–63.PubMedCrossRef

Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–44.PubMedCrossRef

Caviness JN, Driver-Dunckley E, Connor DJ, Sabbagh MN, Hentz JG, Noble B, et al. Defining mild cognitive impairment in Parkinson’s disease. Mov Disord. 2007;22(9):1272–7.PubMedCrossRef

Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson’s patients in the UK. The CamPaIGN study. Brain. 2004;127(Pt 3):550–60.PubMed

Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, et al. 2.MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–24.PubMedCrossRef

Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson’s disease cohort. Brain. 2007;130(Pt 7):1787–98.PubMedCrossRef

Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord. 2006;21(9):1343–9.PubMedCrossRef

Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, et al. Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord. 2002;17(6):1221–6.PubMedCrossRef

Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc. 2003;9(1):17–24.PubMedCrossRef

10.

Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–69.PubMedCrossRef

11.

Pagonabarraga J, Kulisevsky J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A. Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease. Mov Disord. 2008;23(7):998–1005.PubMedCrossRef

12.

Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, et al. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. J Nucl Med. 2011;52(6):848–55. doi:10.2967/jnumed.111.089946.PubMedCrossRef

13.

Apostolova LG, Beyer M, Green AE, Hwang KS, Morra JH, Chou YY, et al. Hippocampal, caudate, and ventricular changes in Parkinson’s disease with and without dementia. Mov Disord. 2010;25(6):687–8.PubMedCrossRef

14.

Huang C, Mattis P, Tang C, Perrine K, Carbon M, Eidelberg D. Metabolic brain networks associated with cognitive function in Parkinson’s disease. Neuroimage. 2007;34(2):714–23.PubMedCrossRef

15.

Liepelt I, Reimold M, Maetzler W, Godau J, Reischl G, Gaenslen A, et al. Cortical hypometabolism assessed by a metabolic ratio in Parkinson’s disease primarily reflects cognitive deterioration-[18F]FDG-PET. Mov Disord. 2009;24(10):1504–11.PubMedCrossRef

16.

Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, et al. Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol. 1992;49(12):1262–8.PubMedCrossRef

17.

Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson’s disease, Parkinson’s disease dementia and dementia with Lewy bodies. Eur J Neurol. 2007;14(12):1357–62.PubMedCrossRef

18.

Hosokai Y, Nishio Y, Hirayama K, Takeda A, Ishioka T, Sawada Y, et al. Distinct patterns of regional cerebral glucose metabolism in Parkinson’s disease with and without mild cognitive impairment. Mov Disord. 2009;24(6):854–62.PubMedCrossRef

19.

Huang C, Mattis P, Perrine K, Brown N, Dhawan V, Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology. 2008;70(16 Pt 2):1470–7.PubMedCrossRef

20.

Pappata S, Santangelo G, Aarsland D, Vicidomini C, Longo K, Bronnick K, et al. Mild cognitive impairment in drug-naive patients with PD is associated with cerebral hypometabolism. Neurology. 2011;77(14):1357–62.PubMedCrossRef

21.

Lyoo CH, Jeong Y, Ryu YH, Rinne JO, Lee MS. Cerebral glucose metabolism of Parkinson’s disease patients with mild cognitive impairment. Eur Neurol. 2010;64(2):65–73.PubMedCrossRef

22.

Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56(1):33–9.PubMedCrossRef

23.

Hobson P, Meara J. Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord. 2004;19(9):1043–9.PubMedCrossRef

24.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.PubMedCrossRef

25.

Teunisse S, Derix MM. The interview for deterioration in daily living activities in dementia: agreement between primary and secondary caregivers. Int Psychogeriatr. 1997;9 Suppl 1:155–62.PubMedCrossRef

26.

Yesavage JA, Brink TL, Rose TL, Lum O, Huang V, Adey M, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17(1):37–49.PubMedCrossRef

27.

Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB, et al. Homocysteine and cognitive impairment in Parkinson’s disease: a biochemical, neuroimaging, and genetic study. Mov Disord. 2009;24(10):1437–44.PubMedCrossRef

28.

Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology. 1974;(24):1019–1025

29.

Parkin AJ, Java RI. Deterioration of frontal lobe function in normal aging: influences of fluid intelligence versus perceptual speed. Neuropsychology. 1999;13(4):539–45.PubMedCrossRef

30.

Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord. 2007;22(12):1689–707.PubMedCrossRef

31.

Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349–56.PubMedCrossRef

32.

Hooper PK, Meikle SR, Eberl S, Fulham MJ. Validation of postinjection transmission measurements for attenuation correction in neurological FDG-PET studies. J Nucl Med. 1996;37(1):128–36.PubMed

33.

Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26(3):839–51. doi:10.1016/j.neuroimage.2005.02.018.PubMedCrossRef

34.

Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38(1):95–113.PubMedCrossRef

35.

Collins DL, Neelin P, Peters TM, Evans AC. Automatic 3D intersubject registration of MR volumetric data in standardized Talairach space. J Comput Assist Tomogr. 1994;18(2):192–205.PubMedCrossRef

36.

Maldjian JA, Laurienti PJ, Burdette JH. Precentral gyrus discrepancy in electronic versions of the Talairach atlas. Neuroimage. 2004;21(1):450–5.PubMedCrossRef

37.

Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19(3):1233–9.PubMedCrossRef

38.

Minoshima S, Frey KA, Foster NL, Kuhl DE. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19(4):541–7.PubMedCrossRef

39.

Lancaster JL, Woldorff MG, Parsons LM, Liotti M, Freitas CS, Rainey L, et al. Automated Talairach atlas labels for functional brain mapping. Hum Brain Mapp. 2000;10(3):120–31.PubMedCrossRef

40.

Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, et al. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry. 2002;159(5):746–54.PubMedCrossRef

41.

Lozza C, Baron JC, Eidelberg D, Mentis MJ, Carbon M, Marie RM. Executive processes in Parkinson’s disease: FDG-PET and network analysis. Hum Brain Mapp. 2004;22(3):236–45.PubMedCrossRef

42.

Baddeley A. The central executive: a concept and some misconceptions. J Int Neuropsychol Soc. 1998;4(5):523–6.PubMedCrossRef

43.

Diwadkar VA, Carpenter PA, Just MA. Collaborative activity between parietal and dorso-lateral prefrontal cortex in dynamic spatial working memory revealed by fMRI. Neuroimage. 2000;12(1):85–99.PubMedCrossRef

44.

Petrides M, Pandya DN. Comparative cytoarchitectonic analysis of the human and the macaque ventrolateral prefrontal cortex and corticocortical connection patterns in the monkey. Eur J Neurosci. 2002;16(2):291–310PubMedCrossRef

45.

Sauseng P, Klimesch W, Gruber W, Doppelmayr M, Stadler W, Schabus M. The interplay between theta and alpha oscillations in the human electroencephalogram reflects the transfer of information between memory systems. Neurosci Lett. 2002;324(2):121–4.PubMedCrossRef

46.

Lee PH, Yong SW, An YS. Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med. 2008;49(12):2006–11.PubMedCrossRef

47.

Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–9.PubMedCrossRef

48.

Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717–25.PubMedCrossRef

49.

Derejko M, Slawek J, Wieczorek D, Brockhuis B, Dubaniewicz M, Lass P. Regional cerebral blood flow in Parkinson’s disease as an indicator of cognitive impairment. Nucl Med Commun. 2006;27(12):945–51.PubMedCrossRef

50.

Melzer TR, Watts R, MacAskill MR, Pitcher TL, Livingston L, Keenan RJ, et al. Grey matter atrophy in cognitively impaired Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(2):188–94.PubMedCrossRef

51.

Hu MT, Taylor-Robinson SD, Chaudhuri KR, Bell JD, Labbe C, Cunningham VJ, et al. Cortical dysfunction in non-demented Parkinson’s disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000;123(Pt 2):340–52.PubMedCrossRef

52.

Eckert T, Tang C, Eidelberg D. Assessment of the progression of Parkinson’s disease: a metabolic network approach. Lancet Neurol. 2007;6(10):926–32.PubMedCrossRef

53.

Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson’s disease. Brain. 2007;130(Pt 7):1834–46.PubMedCrossRef

Title: Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease
Authors: David Garcia-Garcia
Pedro Clavero
Carmen Gasca Salas
Isabel Lamet
Javier Arbizu
Rafael Gonzalez-Redondo
Jose A. Obeso
Maria C. Rodriguez-Oroz
Publication date: 01-11-2012
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 11/2012
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-012-2198-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2012

Small-animal PET imaging of the type 1 and type 2 cannabinoid receptors in a photothrombotic stroke model

Validation of a new protocol for 18F-FDG infusion using an automatic combined dispenser and injector system

3D dosimetry in patients with early breast cancer undergoing Intraoperative Avidination for Radionuclide Therapy (IART®) combined with external beam radiation therapy

The distribution of FDG at PET examinations constitutes a relative mechanism: significant effects at activity quantification in patients with a high muscular uptake

90Y-based PET and SPECT/CT imaging in locoregional brain treatment for high-grade gliomas: retrospective fusion with MRI

Initial investigation of 18F-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery